TWI762444B - 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血 - Google Patents

使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血 Download PDF

Info

Publication number
TWI762444B
TWI762444B TW105114763A TW105114763A TWI762444B TW I762444 B TWI762444 B TW I762444B TW 105114763 A TW105114763 A TW 105114763A TW 105114763 A TW105114763 A TW 105114763A TW I762444 B TWI762444 B TW I762444B
Authority
TW
Taiwan
Prior art keywords
individual
certain embodiments
actriib
seq
signaling inhibitor
Prior art date
Application number
TW105114763A
Other languages
English (en)
Chinese (zh)
Other versions
TW201709927A (zh
Inventor
肯尼斯Ｍ 艾堤
艾德拉曼 拉丹
拉傑許 喬普拉
傑 貝克斯壯
Original Assignee
美商西建公司
美商艾瑟勒朗法瑪公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商西建公司, 美商艾瑟勒朗法瑪公司 filed Critical 美商西建公司
Publication of TW201709927A publication Critical patent/TW201709927A/zh
Application granted granted Critical
Publication of TWI762444B publication Critical patent/TWI762444B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW105114763A 2015-05-13 2016-05-12 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血 TWI762444B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562161136P 2015-05-13 2015-05-13
US62/161,136 2015-05-13
US201562173836P 2015-06-10 2015-06-10
US62/173,836 2015-06-10
US201562243457P 2015-10-19 2015-10-19
US62/243,457 2015-10-19

Publications (2)

Publication Number Publication Date
TW201709927A TW201709927A (zh) 2017-03-16
TWI762444B true TWI762444B (zh) 2022-05-01

Family

ID=57248528

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110148304A TWI814187B (zh) 2015-05-13 2016-05-12 使用ACTRII配位體捕捉以治療β-地中海型貧血
TW105114763A TWI762444B (zh) 2015-05-13 2016-05-12 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW110148304A TWI814187B (zh) 2015-05-13 2016-05-12 使用ACTRII配位體捕捉以治療β-地中海型貧血

Country Status (15)

Country Link
US (1) US20180125928A1 (OSRAM)
EP (1) EP3294320A4 (OSRAM)
JP (2) JP6976859B2 (OSRAM)
KR (1) KR102640198B1 (OSRAM)
CN (1) CN107847562A (OSRAM)
AU (2) AU2016261913B2 (OSRAM)
CA (1) CA2985777A1 (OSRAM)
HK (1) HK1251157A1 (OSRAM)
IL (2) IL284686B2 (OSRAM)
JO (1) JOP20160092B1 (OSRAM)
MY (1) MY189601A (OSRAM)
PH (1) PH12017502079A1 (OSRAM)
TN (1) TN2017000468A1 (OSRAM)
TW (2) TWI814187B (OSRAM)
WO (1) WO2016183280A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PT2340031T (pt) 2008-08-14 2019-07-25 Acceleron Pharma Inc Armadilhas de gdf para uso no tratamento de anemia
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
BR112016029226A2 (pt) 2014-06-13 2017-10-17 Acceleron Pharma Inc métodos e composições para o tratamento de úlceras
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
FI3227675T3 (fi) 2014-12-03 2023-05-25 Celgene Corp Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP4190805A3 (en) 2015-05-20 2023-08-16 Celgene Corporation In vitro cell culture methods for beta-thalassemia using activin type ii receptor ligand traps
EP3370754A4 (en) 2015-11-04 2019-10-23 Acceleron Pharma Inc. METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
JP7072507B2 (ja) 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
MX2019001043A (es) 2016-07-27 2019-09-26 Acceleron Pharma Inc Metodos y composiciones para el tratamiento de la mielofibrosis.
JP7051846B2 (ja) 2016-11-10 2022-04-11 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
HUE068733T2 (hu) * 2017-06-14 2025-01-28 Celgene Corp Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
EP3788065B1 (en) 2018-04-30 2025-08-27 The Children's Hospital Of Philadelphia Improving anemias by combining agents
CA3098679A1 (en) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
CN112969471A (zh) * 2018-10-31 2021-06-15 细胞基因公司 使用激活素-actrii配体陷阱治疗具有环状铁粒幼细胞的受试者中由极低、低或中等风险的骨髓增生异常综合征引起的贫血
CN114302882A (zh) 2019-07-19 2022-04-08 威佛（国际）股份公司 用于治疗输血依赖型β-地中海贫血（tdt）的膜铁转运蛋白抑制剂
CN112924684B (zh) * 2019-12-05 2022-07-29 中国科学院大连化学物理研究所 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
BR112022020628A2 (pt) * 2020-04-13 2022-11-29 Celgene Corp Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof
EP4240399A4 (en) * 2020-11-06 2024-10-09 Acceleron Pharma Inc. FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS
EP4274600A4 (en) * 2021-01-08 2024-11-20 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY HYPERTENSION
JP2024504349A (ja) 2021-01-20 2024-01-31 ビフォー （インターナショナル） エージー 骨髄異形成症候群（ｍｄｓ）の処置において使用するためのフェロポーチン阻害剤
WO2025003139A1 (en) 2023-06-26 2025-01-02 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh)
WO2025122830A1 (en) * 2023-12-08 2025-06-12 Keros Therapeutics, Inc. Methods of using activin receptor type ii signaling inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247A (en) * 1845-11-01 Jordan l
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
EP2124999B1 (en) * 2006-12-18 2012-10-03 Acceleron Pharma, Inc. Activin-actrii antagonists and uses for treating anemia
KR20220002710A (ko) * 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
PT2340031T (pt) * 2008-08-14 2019-07-25 Acceleron Pharma Inc Armadilhas de gdf para uso no tratamento de anemia
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
DK3875104T3 (da) * 2011-10-17 2025-02-03 Acceleron Pharma Inc Sammensætninger til behandling af ineffektiv erytropoiese
CA2868466A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies, Inc. Subcutaneous administration of iduronate-2-sulfatase
CN112957462A (zh) * 2012-10-24 2021-06-15 细胞基因公司 用于治疗贫血的方法
JP6401171B2 (ja) * 2012-10-24 2018-10-03 セルジーン コーポレイション 貧血の治療に使用するためのバイオマーカー
PT3502240T (pt) * 2012-11-27 2021-08-11 Childrens Medical Ct Corp Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal

Also Published As

Publication number Publication date
NZ737043A (en) 2025-02-28
TW201709927A (zh) 2017-03-16
AU2016261913A1 (en) 2017-11-30
PH12017502079A1 (en) 2018-06-11
AU2021258087A1 (en) 2021-11-25
TN2017000468A1 (en) 2019-04-12
WO2016183280A1 (en) 2016-11-17
AU2016261913B2 (en) 2021-08-12
IL255527A (en) 2018-01-31
EP3294320A4 (en) 2018-12-26
TWI814187B (zh) 2023-09-01
TW202231294A (zh) 2022-08-16
IL284686B2 (en) 2023-05-01
IL255527B (en) 2021-07-29
MY189601A (en) 2022-02-18
AU2021258087B2 (en) 2023-04-27
KR102640198B1 (ko) 2024-02-23
US20180125928A1 (en) 2018-05-10
EP3294320A1 (en) 2018-03-21
CN107847562A (zh) 2018-03-27
IL284686B (en) 2023-01-01
HK1251157A1 (zh) 2019-01-25
JP2018520094A (ja) 2018-07-26
IL284686A (en) 2021-08-31
JP6976859B2 (ja) 2021-12-08
JP2021191755A (ja) 2021-12-16
KR20180006437A (ko) 2018-01-17
JOP20160092B1 (ar) 2023-03-28
CA2985777A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
TWI762444B (zh) 使用ＡＣＴＲＩＩ配位體捕捉以治療β-地中海型貧血
JP7496686B2 (ja) 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
JP6714646B2 (ja) アクチビン−ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用
AU2015358469B2 (en) Activin-ActRII antagonists and uses for treating anemia
US20230142386A1 (en) Activin-actrii antagonists and uses for treating anemia
HK1254086B (en) Activin-actrii antagonists and uses for treating bone and other disorders
NZ747422B2 (en) Activin-actrii antagonists and uses for treating bone and other disorders
HK1226958A1 (en) Activin-actrii antagonists and uses for increasing red blood cell levels